litlas
Log inCreate account

Ashish M. Kamat

Active 2003–2025

215
Papers
25,017
Citations
91
h-index
195
i10-index

Citations

Citations per year for Ashish M. Kamat1992: 3 citations1993: 1 citations2001: 2 citations2003: 1 citations2004: 4 citations2005: 14 citations2006: 15 citations2007: 26 citations2008: 41 citations2009: 61 citations2010: 86 citations2011: 105 citations2012: 115 citations2013: 112 citations2014: 108 citations2015: 108 citations2016: 169 citations2017: 185 citations2018: 184 citations2019: 658 citations2020: 914 citations2021: 896 citations2022: 722 citations2023: 686 citations2024: 1,327 citations2025: 720 citations2026: 17 citations1994–2000: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,034 citing papers, 21% of this breakdownChina: 1,231 citing papers, 12.7% of this breakdownItaly: 590 citing papers, 6.1% of this breakdownUnited Kingdom: 470 citing papers, 4.8% of this breakdownGermany: 465 citing papers, 4.8% of this breakdownFrance: 439 citing papers, 4.5% of this breakdownCanada: 387 citing papers, 4% of this breakdownSpain: 340 citing papers, 3.5% of this breakdownNetherlands: 321 citing papers, 3.3% of this breakdownJapan: 302 citing papers, 3.1% of this breakdownAustria: 294 citing papers, 3% of this breakdownSwitzerland: 194 citing papers, 2% of this breakdown
0%21%Other 27.2%

Institutions

Fields

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology18.7%
  • Immunology and Microbiology5%
  • Engineering1.1%
  • Neuroscience0.9%
  • Computer Science0.6%
  • Other1.8%

Topics

  • Bladder and Urothelial Cancer Treatments18%
  • Urinary and Genital Oncology Studies9.7%
  • Cancer Immunotherapy and Biomarkers5.4%
  • Ferroptosis and cancer prognosis2.8%
  • Epigenetics and DNA Methylation2.4%
  • Immunotherapy and Immune Responses2.2%
  • Other59.5%

Coauthors

All papers

Open in search
  1. Bladder cancer

    Authors: Ashish M. Kamat, Noah M. Hahn, Jason A. Efstathiou, Seth P. Lerner, Per‐Uno Malmström, Woonyoung Choi, Charles C. Guo, Yair Lotan, Wassim Kassouf - The Lancet 2016 cited by 1,453

  2. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

    Authors: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet Oncology 2021 cited by 533

  3. Current best practice for bladder cancer: a narrative review of diagnostics and treatments

    Authors: Éva Compérat, Mahul B. Amin, Richard Cathomas, Ananya Choudhury, Maria De Santis, Ashish M. Kamat, Arnulf Stenzl, Harriet C. Thoeny, J. Alfred Witjes - The Lancet 2022 cited by 434

  4. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

    Authors: Ibrahim Jubber, Sean Ong, Laura Bukavina, Peter C. Black, Éva Compérat, Ashish M. Kamat, Lambertus A. Kiemeney, Nathan Lawrentschuk, Seth P. Lerner, Joshua J. Meeks, Holger Moch, Andrea Necchi, Valeria Panebianco, Srikala S. Sridhar, Ariana Znaor, James W.F. Catto, Marcus Cumberbatch - European Urology 2023 cited by 481

  5. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

    Authors: Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne Schuckman, Tracy M. Downs, Robert S. Svatek, Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey L. Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O’Donnell, David G. Sawutz, Richard Philipson, Ruth Coll, Vikram M. Narayan, F. Peter Treasure, Seppo Ylä‐Herttuala, Nigel Parker, Colin P. Dinney - The Lancet Oncology 2020 cited by 442

  6. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

    Authors: Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene O. Siefker‐Radtke, Matthew T. Campbell, Rebecca S. Tidwell, Charles C. Guo, Ashish M. Kamat, Surena F. Matin, John C. Araujo, Amishi Y. Shah, Pavlos Msaouel, Paul G. Corn, Jianbo Wang, John Papadopoulos, Shalini S. Yadav, Jorge Blando, Fei Duan, Sreyashi Basu, Wenbin Liu, Yu Shen, Yuwei Zhang, Marc Macaluso, Ying Wang, Jianfeng Chen, Jianhua Zhang, P. Andrew Futreal, Colin P. Dinney, James P. Allison, Sangeeta Goswami, Padmanee Sharma - Nature Medicine 2020 cited by 313

  7. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

    Authors: Sam S. Chang, Bernard H. Bochner, Roger Chou, Robert Dreicer, Ashish M. Kamat, Seth P. Lerner, Yair Lotan, Joshua J. Meeks, Jeff M. Michalski, Todd M. Morgan, Diane Zipursky Quale, Jonathan E. Rosenberg, Anthony L. Zietman, Jeffrey M. Holzbeierlein - The Journal of Urology 2017 cited by 940

  8. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test

    Authors: Juan Pablo Hinestrosa, Razelle Kurzrock, Jean M. Lewis, Nicholas J. Schork, Gregor Schroeder, Ashish M. Kamat, Andrew M. Lowy, Ramez N. Eskander, Orlando Perrera, David Searson, Kiarash Rastegar, Jake R. Hughes, V. Espinosa Ortiz, Iryna Clark, Heath I. Balcer, Larry Arakelyan, Robert Turner, Paul R. Billings, Mark J. Adler, Scott M. Lippman, Rajaram Krishnan - Communications Medicine 2022 cited by 153

  9. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

    Authors: Marcus Cumberbatch, Ibrahim Jubber, Peter C. Black, Francesco Esperto, Jonine D. Figueroa, Ashish M. Kamat, Lambertus A. Kiemeney, Yair Lotan, Karl H. Pang, Debra T. Silverman, Ariana Znaor, James W.F. Catto - European Urology 2018 cited by 840

  10. Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

    Authors: Ashish M. Kamat, Richard Sylvester, Andreas Böhle, Joan Palou, Donald L. Lamm, Maurizio Brausi, Mark S. Soloway, Raj Persad, Roger Buckley, Marc Colombel, J. Alfred Witjes - Journal of Clinical Oncology 2016 cited by 413

  11. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita

    Authors: Jeremy Yuen‐Chun Teoh, Junjie Huang, Wendy Yuet-Kiu Ko, Veeleah Lok, Peter Choi, Chi‐Fai Ng, Shomik Sengupta, Hugh Mostafid, Ashish M. Kamat, Peter C. Black, Shahrokh F. Shariat, Marek Babjuk, Martin C. S. Wong - European Urology 2020 cited by 262

  12. CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients

    Authors: Chrysoula I. Liakou, Ashish M. Kamat, Derek Ng Tang, Hong Chen, Jingjing Sun, Patricia Troncoso, Christopher J. Logothetis, Padmanee Sharma - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 538

  13. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Authors: Marcus Cumberbatch, Beat Foerster, James W.F. Catto, Ashish M. Kamat, Wassim Kassouf, Ibrahim Jubber, Shahrokh F. Shariat, Richard Sylvester, Paolo Gontero - European Urology 2018 cited by 332

  14. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19

    Authors: Niyati Lobo, Nathan A. Brooks, Alexandre R. Zlotta, Jeffrey D. Cirillo, Stephen A. Boorjian, Peter C. Black, Joshua J. Meeks, Trinity J. Bivalacqua, Paolo Gontero, Gary D. Steinberg, David J. McConkey, Marko Babjuk, J. Alfred Witjes, Ashish M. Kamat - Nature Reviews Urology 2021 cited by 147

  15. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

    Authors: Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin, Ashish M. Kamat, Richard Zigeuner, Eiji Kikuchi, Yair Lotan, Alon Z. Weizer, Jay D. Raman, Christopher G. Wood - Cancer 2009 cited by 1,134

  16. Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective

    Authors: Jeremy Yuen‐Chun Teoh, Ashish M. Kamat, Peter C. Black, Petros Grivas, Shahrokh F. Shariat, Marek Babjuk - Nature Reviews Urology 2022 cited by 196

  17. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer

    Authors: Ryan L. Steinberg, Lewis J. Thomas, Nathan A. Brooks, Sarah L. Mott, Andrew Vitale, Trafford Crump, Mounica Y. Rao, Marcus J. Daniels, Jonathan Wang, Supriya Nagaraju, William C. DeWolf, Donald L. Lamm, Max Kates, M. Eric Hyndman, Ashish M. Kamat, Trinity J. Bivalacqua, Kenneth G. Nepple, Michael A. O’Donnell - The Journal of Urology 2019 cited by 182

  18. Data Sharing Under the General Data Protection Regulation

    Authors: Antonia Vlahou, Dara Hallinan, Rolf Apweiler, Àngel Argilés, Joachim Beige, Ariela Benigni, Rainer Bischoff, Peter C. Black, Franziska Boehm, Jocelyn Céraline, George P. Chrousos, Christian Delles, Pieter Evenepoel, Ivo Fridolin, Griet Glorieux, Alain J. van Gool, Isabel Heidegger, John P. A. Ioannidis, Joachim Jankowski, Vera Jankowski, Cármen Jerónimo, Ashish M. Kamat, Rosalinde Masereeuw, Gert Mayer, Harald Mischak, Alberto Ortíz, Giuseppe Remuzzi, Peter Rossing, Joost P. Schanstra, Bernd J. Schmitz‐Dräger, Goce Spasovski, Jan A. Staessen, Dimitrios Stamatialis, Peter Stenvinkel, Christoph Wanner, Stephen B. Williams, Faı̈ez Zannad, Carmine Zoccali, Raymond Vanholder - Hypertension 2021 cited by 130

  19. What Is the Significance of Variant Histology in Urothelial Carcinoma?

    Authors: Niyati Lobo, Shahrokh F. Shariat, Charles C. Guo, Mario I. Fernández, Wassim Kassouf, Ananya Choudhury, Jianjun Gao, Stephen B. Williams, Matthew D. Galsky, John A. Taylor, Morgan Rouprêt, Ashish M. Kamat - European Urology Focus 2019 cited by 244

  20. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

    Authors: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, David D‘Andrea, Francesco Soria, Paweł Rajwa, Hadi Mostafaei, Éva Compérat, Alessia Cimadamore, Marco Moschini, Jeremy Yuen‐Chun Teoh, Dmitry Enikeev, Évanguelos Xylinas, Yair Lotan, Juan Palou, Paolo Gontero, Marko Babjuk, J. Alfred Witjes, Ashish M. Kamat, Morgan Rouprêt, Shahrokh F. Shariat, Benjamin Pradère - European Urology Oncology 2021 cited by 112

  21. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group

    Authors: Wei Shen Tan, Gary D. Steinberg, J. Alfred Witjes, Roger Li, Shahrokh F. Shariat, Morgan Rouprêt, Marko Babjuk, Trinity J. Bivalacqua, Sarah P. Psutka, Stephen B. Williams, Michael S. Cookson, Juan Palou, Ashish M. Kamat - European Urology Oncology 2022 cited by 86

  22. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

    Authors: Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan, Ashish M. Kamat, Derek S. Ng Tang, Jingjing Sun, Geoffrey Y. Ku, Patricia Troncoso, Christopher J. Logothetis, James P. Allison, Padmanee Sharma - Clinical Cancer Research 2010 cited by 461

  23. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer

    Authors: Wei Shen Tan, Ian M. McElree, Facundo Davaro, Ryan L. Steinberg, Kelly K. Bree, Neema Navai, Colin P. Dinney, Michael A. O’Donnell, Roger Li, Ashish M. Kamat, Vignesh T. Packiam - European Urology Oncology 2023 cited by 36

  24. Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

    Authors: Max Kates, Andrés Matoso, Woonyoung Choi, Alexander S. Baras, Marcus J. Daniels, Kara A. Lombardo, Aaron Brant, Nina Mikkilineni, David J. McConkey, Ashish M. Kamat, Robert S. Svatek, Sima P. Porten, Joshua J. Meeks, Seth P. Lerner, Colin P. Dinney, Peter C. Black, James M. McKiernan, Chris Anderson, Charles G. Drake, Trinity J. Bivalacqua - Clinical Cancer Research 2019 cited by 166